Common Contracts
6 similar Underwriting Agreement contracts by Alset EHome International Inc., Sunshine Biopharma, Inc, Provectus Biopharmaceuticals, Inc., T1V, Inc.
UNDERWRITING AGREEMENT Dated [____________] [__], 2023 Between T1V, INC. (a Delaware corporation), SELLING STOCKHOLDERS OF T1V, INC. named on Schedule II attached hereto (for the sole purpose of the Over-Allotment Option) And EF HUTTON, Division of...Underwriting Agreement • January 24th, 2023 • T1V, Inc. • Services-computer programming, data processing, etc. • New York
The undersigned, T1V, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and certain stockholders of the Company (the “Selling Stockholders”) named on Schedule II attached hereto (for the sole purpose of the Over-Allotment Option), hereby confirm their agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which EF Hutton, division of Benchmark Investments, LLC (“EF Hutton”), is acting as representative to the several Underwriters (in such capacity, the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein. References made to Selling Stockholders shall relate solely to the Over-Allotment Opti
UNITS Sunshine Biopharma, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 14th, 2022 • Sunshine Biopharma, Inc • Services-commercial physical & biological research • New York
The undersigned, Sunshine Biopharma, Inc., a corporation formed under the laws of the State of Colorado (collectively, with its Subsidiaries, the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (“Aegis” or the “Underwriter”) on the terms and conditions set forth herein. The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering”.
UNITS Sunshine Biopharma, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 9th, 2022 • Sunshine Biopharma, Inc • Services-commercial physical & biological research • New York
The undersigned, Sunshine Biopharma, Inc., a corporation formed under the laws of the State of Colorado (collectively, with its Subsidiaries, the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (“Aegis” or the “Underwriter”) on the terms and conditions set forth herein. The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering”.
6,311,637 UNITS Alset EHome International Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • May 14th, 2021 • Alset EHome International Inc. • Real estate • New York
The undersigned, Alset EHome International Inc., a corporation formed under the laws of the State of Delaware (collectively, with its Subsidiaries, the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named on Schedule 1 hereto for which Aegis Capital Corp. is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein. The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering”.
●] UNITS Alset EHome International Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • May 4th, 2021 • Alset EHome International Inc. • Real estate • New York
The undersigned, Alset EHome International Inc., a corporation formed under the laws of the State of Delaware (collectively, with its Subsidiaries, the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named on Schedule 1 hereto for which Aegis Capital Corp. is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein. The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering”.
17,500,000 SHARES OF COMMON STOCK AND 17,500,000 WARRANTS OF PROVECTUS BIOPHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • June 19th, 2015 • Provectus Biopharmaceuticals, Inc. • Pharmaceutical preparations • New York
The undersigned, Provectus Biopharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Provectus Biopharmaceuticals, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for whom Maxim Group LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
